The Adult Leukemia Program at the Icahn School of Medicine at Mount Sinai is an internationally recognized comprehensive effort. It is dedicated to the clinical care of patients with acute and chronic leukemia, with a focus on the development of novel therapies for both forms. The program generates translational research to understand the underlying causes of leukemias and inform development of future therapeutics.
The clinical care team comprises an expert group of dedicated medical hematologist-oncologists, bone marrow transplant physicians, hematopathologists, oncology pharmacists, nurse practitioners, physician assistants, nurses, social workers, and medical assistants. The whole team is dedicated to delivering quality and compassionate care. In addition, the care team includes specialists from The Mount Sinai Hospital. We work closely with experts in infectious disease, pulmonary and critical care, nephrology, cardiology, gastroenterology, interventional radiology, and palliative care.
In addition to clinical care, the Adult Leukemia Program is dedicated to understanding the biologic basis of leukemia. Our goal is to develop novel therapies that improve patient outcomes. Through extensive collaboration with laboratory researchers, we have built a research infrastructure that brings findings from the laboratory directly to the clinic. Patients have access to many state-of-the-art clinical trials (see below). Our research addresses targeted therapies, novel antibodies, bispecific T-cell engagers, and hematopoietic stem cell products.